1 December 2021

Renske van den Bijgaart and Gosse Adema, theme Cancer development and immune defence received a grant from Villa Joep, entitled “Bifunctional anti-GD2 antibodies co-targeting innate immune checkpoints to improve immunotherapy of Neuroblastoma”.

In this grant the, ROI research team will develop novel bifunctional monoclonal antibody formats that target the GD2 tumor-associated antigen on Neuroblastoma (NBL) and locally activate the immune system.

Renske van den Bijgaart and Gosse Adema both are from the Radiotherapy & OncoImmunology (ROI) laboratory (Department of Radiation Oncology) and in collaboration with the Prinses Maxima Center (Peter Hoogerbrugge) they received this Villa Joep grant of 410K Euro.

read more

Related news items


What does the shingles vaccine teach us about other vaccines? Investigating the role of trained immunity

27 January 2022

The vaccine for shingles, a condition that causes itching, pain, and blisters, is 90% effective, even in elderly. This is remarkable, since most vaccines offer less protection in elderly. Radboudumc is investigating why this vaccine works so well and how it might help us to develop better vaccines.

read more

RIMLS PhD retreat 2022 Register now

25 January 2022

This year, the 2-day RIMLS PhD retreat will be held on 14 & 15 July 2022 in the Koningshof, Veldhoven. We are aiming for a live event again!

read more

Most COVID-19 ICU survivors experience symptoms one year after ICU admission Publication in JAMA

25 January 2022

75% of the COVID-19 survivors who were treated in the Intensive Care Unit (ICU) experience physical, mental and/or cognitive problems one-year post ICU. This shows the large-scale MONITOR-IC study led by Radboudumc.

read more

Laurens Verscheijden awarded doctorate degree 'cum laude'

19 January 2022

Laurens Verscheijden of the Department of Pharmacology and Toxicology, defended his PhD thesis, entitled "Mechanistic models for the prediction of brain drug exposure and response in the paediatric population: A virtual child reaching maturation.

read more